Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,270 | 649 | 92.6% |
| Education | $826.11 | 22 | 7.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,084 | 133 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,746 | 129 | $0 (2024) |
| PFIZER INC. | $953.88 | 62 | $0 (2024) |
| Merck Sharp & Dohme LLC | $802.75 | 53 | $0 (2023) |
| Celgene Corporation | $550.70 | 34 | $0 (2024) |
| Incyte Corporation | $544.55 | 23 | $0 (2024) |
| Astellas Pharma US Inc | $532.65 | 15 | $0 (2024) |
| Amgen Inc. | $472.80 | 21 | $0 (2023) |
| Daiichi Sankyo Inc. | $423.42 | 31 | $0 (2024) |
| Eisai Inc. | $420.96 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,733 | 92 | E.R. Squibb & Sons, L.L.C. ($282.99) |
| 2023 | $1,476 | 87 | Novartis Pharmaceuticals Corporation ($245.75) |
| 2022 | $1,908 | 113 | Novartis Pharmaceuticals Corporation ($430.88) |
| 2021 | $920.43 | 61 | Novartis Pharmaceuticals Corporation ($260.46) |
| 2020 | $467.00 | 30 | E.R. Squibb & Sons, L.L.C. ($90.58) |
| 2019 | $1,690 | 106 | E.R. Squibb & Sons, L.L.C. ($357.57) |
| 2018 | $1,424 | 92 | Novartis Pharmaceuticals Corporation ($298.43) |
| 2017 | $1,478 | 90 | Novartis Pharmaceuticals Corporation ($348.91) |
All Payment Transactions
671 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $27.08 | General |
| Category: Hematology | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Oncology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.50 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $96.00 | General |
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Oncology | ||||||
| 12/04/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.64 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $27.71 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/13/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $17.89 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.63 | General |
| Category: Hematology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.66 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $2.41 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $96.00 | General |
| 10/14/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Oncology | ||||||
| 10/07/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $9.16 | General |
| Category: Cardiovascular | ||||||
| 09/26/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $9.47 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 469 | 1,003 | $180,340 | $71,213 |
| 2022 | 6 | 510 | 1,276 | $215,222 | $83,695 |
| 2021 | 8 | 555 | 1,401 | $234,967 | $92,522 |
| 2020 | 8 | 580 | 1,318 | $220,362 | $82,240 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 106 | 403 | $58,080 | $24,268 | 41.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 119 | 146 | $39,709 | $14,401 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 129 | 258 | $36,461 | $14,377 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 147 | $30,523 | $12,841 | 42.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $15,567 | $5,324 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 186 | 527 | $74,476 | $30,643 | 41.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 105 | 464 | $66,872 | $25,281 | 37.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 107 | 127 | $34,541 | $12,848 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 61 | 107 | $22,217 | $8,963 | 40.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $12,708 | $4,283 | 33.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $4,408 | $1,677 | 38.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 183 | 545 | $77,019 | $31,487 | 40.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 125 | 533 | $76,816 | $29,633 | 38.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 115 | 139 | $37,805 | $14,619 | 38.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 48 | 48 | $15,250 | $5,804 | 38.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 45 | $9,344 | $3,912 | 41.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 25 | $10,019 | $3,810 | 38.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 14 | 55 | $4,307 | $1,641 | 38.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $4,408 | $1,617 | 36.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 204 | 583 | $82,390 | $29,279 | 35.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 112 | 398 | $57,360 | $22,600 | 39.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 110 | 128 | $34,813 | $13,623 | 39.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 34 | 37 | $14,827 | $5,794 | 39.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 45 | 45 | $14,297 | $4,568 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 34 | 36 | $7,475 | $2,738 | 36.6% |
About Waris Waris
Waris Waris is a Internal Medicine healthcare provider based in Logan, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891807822.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Waris Waris has received a total of $11,096 in payments from pharmaceutical and medical device companies, with $1,733 received in 2024. These payments were reported across 671 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($10,270).
As a Medicare-enrolled provider, Waris has provided services to 2,114 Medicare beneficiaries, totaling 4,998 services with total Medicare billing of $329,671. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Logan, WV
- Active Since 08/31/2006
- Last Updated 01/07/2010
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891807822
Products in Payments
- OPDIVO (Biological) $1,387
- KEYTRUDA (Biological) $738.47
- KISQALI (Drug) $538.12
- TASIGNA (Drug) $359.96
- ELIQUIS (Drug) $336.78
- Lenvima (Drug) $329.56
- Enhertu (Drug) $285.20
- JAKAFI (Drug) $266.14
- AFINITOR (Drug) $254.95
- MEKINIST (Drug) $236.29
- LUMAKRAS (Drug) $230.33
- XTANDI (Drug) $229.92
- RYDAPT (Drug) $189.20
- CHANTIX (Drug) $187.64
- LIBTAYO (Biological) $177.77
- REBLOZYL (Biological) $172.09
- Xtandi (Drug) $159.77
- Pomalyst (Drug) $153.28
- IMBRUVICA (Drug) $146.00
- LYNPARZA (Drug) $142.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Logan
Steven Salisbury, Md, MD
Internal Medicine — Payments: $9,965
Dr. Kozhaya Mallah, Md, MD
Internal Medicine — Payments: $8,931
Dr. Jonathan Rhee, M.d, M.D
Internal Medicine — Payments: $7,036
Haytham Alkhaimy
Internal Medicine — Payments: $6,170
Radhakrishna Kukkillaya, M.d, M.D
Internal Medicine — Payments: $3,396
Dr. John Ireton, D.o, D.O
Internal Medicine — Payments: $1,675